乳腺癌体积倍增时间与ER、PR、HER-2及Ki-67的相关性研究-东南大学学报医学版

乳腺癌体积倍增时间与ER、PR、HER-2及Ki-67的相关性研究

单位：南京医科大学附属无锡人民医院超声医学科, 江苏无锡 214023

分类号：R737.9;R445.1

出版年·卷·期（页码）：2016·35·第六期（878-881）

摘要：

目的：使用三维超声评估乳腺癌的肿瘤体积倍增时间（tumour volume doubling time，TVDT），分析TVDT与病理学指标的相关性。方法：69例至少有2次三维超声检查（间隔至少3个月）的乳腺癌病人纳入研究。根据公式计算出TVDT，并与病理学指标进行统计学分析。结果：本组TVDT平均天数为（185±126）d（66~521 d，中位天数164 d）。乳腺癌患者不同年龄、月经状态、病理类型、淋巴结转移情况、组织学分级、诺丁汉预后指数（Nottingham prognostic index，NPI）及HER-2的患者TVDT差异无统计学意义（P>0.05）。不同乳腺癌家族史、ER、PR、Ki-67及乳腺癌分子亚型的乳腺癌患者TVDT差异有统计学意义（P<0.05）。乳腺癌分子亚型中ER阳性组TVDT为（234±156）d，HER-2过表达组为（184±71）d，三阴性组为（127±48）d。结论：乳腺癌TVDT与乳腺癌预后分子病理学标志物ER、PR、Ki-67及分子亚型有关，其中三阴性乳腺癌生长最快。

Objective: To evaluate tumor volume doubling time(TVDT) of breast cancer with three-dimensional ultrasound(3D-US), and analyze the correlation between TVDT and pathological indexes. Methods: A total of 69 patients with breast cancer were enrolled in the study. Patients with breast cancer scanned by 3D-US at least twice(with an interval of 3 months or more)were recruited. The results of TVDT were calculated according to the formula and statistically compared with pathological indexes. Results: Mean TVDT was(185±126) d(range 66 to 521, median 164). The mean TVDT of patients with ER positive was(234±156) d, with overexpression of HER-2 was(184±71) d, and with triple-negative breast cancer was(127±48) d. There were no statistic significance in TVDT between different patient age, menstrual cyclicity, pathological classification, lymph node metastasis, histological grade, Nottingham prognostic index(NPI) and HER-2 expression(all P>0.05). There were significant relationships between TVDT and a family history, ER, PR, Ki-67 or molecular subtypes of breast cancer(all P<0.05). Conclusion: TVDT of breast cancer is associated with prognostic biomarkers of ER, PR, Ki-67 and molecular subtypes. Triple-negative breast cancer has the fastest growth rate.

参考文献：

[1] MACKINTOSH J A,MARSHALL H M,YANG I A,et al.A retrospective study of volume doubling time in surgically resected non-small cell lung cancer[J].Respirology,2014,19(5):755-762.
[2] BAILEY S L I,SIGAL B M,PLEVRITIS S K.A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years[J].J Natl Cancer Inst,2010,102(16):1263-1271.
[3] 丁炎,周锋盛,陈俊,等.乳腺癌超声造影特征与诺丁汉预后指数的相关性[J].中华内分泌外科杂志,2012,6(2):94-97.
[4] TELANG N.Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer[J].Oncol Lett,2015,10(6):3840-3846.
[5] GARCÍA-FERNÁNDEZ A,CHABRERA C,GARCÍA-FONT M,et al.Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification:analytical survey from 1997 to 2012[J].Tumour Biol,2013,34(4):2349-2355.
[6] 钱柏锋,尹鑫,石欣.乳腺癌循环肿瘤细胞临床研究进展[J].东南大学学报:医学版,2015,34(3):476-478.
[7] YANG Q,CHEN J,LI H J,et al.Clinical features and prognosis analysis of different breast cancer molecular subtypes[J].Zhonghua Zhong Liu Za Zhi,2011,33(1):42-46.
[8] GANDINI S,GUERRIERI-GONZAGA A,PRUNERI G,et al.Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials[J].Ann Oncol,2014,25(3):618-623.
[9] 李振,甄林林.粒细胞集落刺激因子在乳腺癌新辅助化疗中的疗效分析[J].东南大学学报:医学版,2014,33(4):461-464.
[10] GAGLIATO-DDE M,GONZALEZ-ANGULO A M,LEI X,et al.Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer[J].J Clin Oncol,2014,32(8):735-744.
[11] BAILEY S L,SIGAL B M,PLEVRITIS S K.A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years[J].J Natl Cancer Inst,2010,102(16):1263-1271.
[12] PARK S,KOO J S,KIM M S,et al.Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry[J].Breast,2012,21(1):50-57.
[13] LEE J A,KIM K I,BAE J W,et al.Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival[J].Breast Cancer Res Treat,2010,123(1):177-187.
[14] TILANUS-LINTHORST M M,OBDEIJN I M,HOP W C,et al.BRCA1 mutation and young age predict fast breast cancer growth in the Dutch,United Kingdom,and Canadian magnetic resonance imaging screening trials[J].Clin Cancer Res,2007,13(24):7357-7362.
[15] MILLET I,BOUIC-PAGES E,HOA D,et al.Growth of breast cancer recurrences assessed by consecutive MRI[J].BMC Cancer,2011,11:155.
[16] ALZAHRANI E O,ASIRI A,EL-DESSOKY M M,et al.Quiescence as an explanation of Gompertzian tumor growth revisited[J].Math Biosci,2014,254:76-82.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录